| Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors C Shao, G Li, L Huang, S Pruitt, E Castellanos, G Frampton, KR Carson, ... JAMA Network Open 3 (10), e2025109-e2025109, 2020 | 116 | 2020 |
| Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study ZR Reichert, TM Morgan, G Li, E Castellanos, T Snow, FG Dall’Olio, ... Annals of Oncology 34 (1), 111-120, 2023 | 57 | 2023 |
| Real‐world data of palbociclib in combination with endocrine therapy for the treatment of metastatic breast cancer in men AL Kraus, M Yu‐Kite, J Mardekian, MJ Cotter, S Kim, J Decembrino, ... Clinical Pharmacology & Therapeutics 111 (1), 302-309, 2022 | 25 | 2022 |
| Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). CH Bartlett, J Mardekian, M Yu-Kite, MJ Cotter, S Kim, J Decembrino, ... Journal of Clinical Oncology 37 (15_suppl), 1055-1055, 2019 | 18 | 2019 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron health-foundation medicine clinico-genomic databases, flatiron health … T Snow, J Snider, L Comment, S Stergiopoulos, V Fisher, M McCusker, ... medRxiv, 2023.01. 03.22283682, 2023 | 6 | 2023 |
| Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). ES Antonarakis, R Madison, J Snider, T Snow, E Sokol, J Chung, ... Journal of Clinical Oncology 38 (15_suppl), 5527-5527, 2020 | 5 | 2020 |
| CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non–small cell lung cancer (aNSCLC). B Besse, R Madison, CD Cho-Phan, J Snider, T Snow, FG Dall'Olio, ... Journal of Clinical Oncology 40 (16_suppl), 9045-9045, 2022 | 4 | 2022 |
| Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC) A Swaminathan, S Stergiopoulos, J Snider, V Fisher, E Castellanos, ... Cancer Research 81 (13_Supplement), 864-864, 2021 | 4 | 2021 |
| Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset D Backenroth, C Shao, G Li, L Huang, SK Pruitt, E Castellanos, ... Annals of Oncology 30, v761-v762, 2019 | 4 | 2019 |
| Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR … F Batalini, R Madison, DC Pavlick, E Sokol, T Snow, A Sondhi, ... Journal of Clinical Oncology 39 (15_suppl), 10512-10512, 2021 | 3 | 2021 |
| P2. 14-01 Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC H Husain, RW Madison, J Haberberger, C Cho-Phan, J Snider, TD Snow, ... Journal of Thoracic Oncology 17 (9), S156-S157, 2022 | 1 | 2022 |
| Comprehensive genomic profiling (CGP) in breast cancer (BC): Patterns and results from a clinico-genomic database A Rody, N Chaudhary, C Craggs, M Debiasi, G Erb, V Fisher, M McCusker, ... Cancer Research 81 (13_Supplement), 437-437, 2021 | 1 | 2021 |
| Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice. DL Richardson, JCF Quintanilha, R Graf, N Danziger, C Washington, ... Journal of Clinical Oncology 41 (16_suppl), 5583-5583, 2023 | | 2023 |
| Using Multilevel Regression and Poststratification (MRP) to inform estimates of biomarker prevalence for target populations of interest using linked clinico-genomic databases JW Snider, B Beal, L Bouzit, C Cho-Phan, L Comment, G Frampton, ... Cancer Research 83 (7_Supplement), 4257-4257, 2023 | | 2023 |
| 237P Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune … S Chumsri, S Sammons, L Alder, E Sokol, NA Danziger, K Raskina, ... Annals of Oncology 32, S462-S463, 2021 | | 2021 |
| Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC). DG Stover, TM Morgan, R Graf, G Li, E Castellanos, T Snow, ... Journal of Clinical Oncology 39 (15_suppl), e17035-e17035, 2021 | | 2021 |
| Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated … R Graf, R Madison, O Gjoerup, L Zhong, S Morley, S Chopra, L Comment, ... Journal of Clinical Oncology 39 (6_suppl), 142-142, 2021 | | 2021 |
| Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size. SHI Ou, R Madison, T Snow, J Snider, ME McCusker, G Singal, ... Journal of Clinical Oncology 38 (15_suppl), 9591-9591, 2020 | | 2020 |
| Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors treated with pembrolizumab monotherapy (P) after FDA … T Snow, A Swaminathan, J Snider, AB Schrock, G Li, BM Alexander, ... Journal of Clinical Oncology 38 (15_suppl), 3060-3060, 2020 | | 2020 |
